Sánchez de Cos Escuín J, Masa Jiménez F, Disdier Vicente C, de la Cruz Ríos J L, Vergara Fiordia C, Domínguez Retortillo C, Fuentes Otero F
Unidad de Neumología, Hospital San Pedro de Alcántara, Cáceres.
Arch Bronconeumol. 1994 Oct;30(8):375-80.
The utility of neuron-specific enolase (NSE) for the diagnosis and management of small cell lung cancer (SCLC) is analyzed. Serum concentrations of NSE were measured in 69 healthy adults, 106 patients with non-neoplastic pneumopathy (NNP), 16 with pulmonary metastasis of extrapulmonary origin (PMEO), 126 with non-small cell lung cancer (NSCLC), and 77 with SCLC. Repeated analyses were carried out for patients in the last group during and after treatment, and survival time was recorded. NSE was high in 77.6% of patients with SCLC [50% in cases with limited disease (LD) and 93.6% in those with extensive disease (ED)]. NSE was high in 10.3% of those with NSCLC, in 11.5% of those with PMEO, and in 2.8% of those with NNP. NSE decreased 100% in SCLC patients achieving full remission after treatment and in 25% of those responding poorly. Later, this marker increased in 81.2% of those experiencing relapse, and in 6.2% of these the increased preceded symptoms. Initial NSE concentrations had prognostic value (p = 0.003) that was independent of disease stage (LD or ED). NSE is of great diagnostic and prognostic value in SCLC, accurately reflecting tumor size. Posttreatment changes closely parallel disease activity.
分析神经元特异性烯醇化酶（NSE）在小细胞肺癌（SCLC）诊断和管理中的效用。测定了69名健康成年人、106名非肿瘤性肺病（NNP）患者、16名肺外来源肺转移（PMEO）患者、126名非小细胞肺癌（NSCLC）患者和77名SCLC患者的血清NSE浓度。对最后一组患者在治疗期间和治疗后进行了重复分析，并记录了生存时间。77.6%的SCLC患者NSE升高[局限性疾病（LD）患者中为50%，广泛性疾病（ED）患者中为93.6%]。NSCLC患者中10.3%的人NSE升高，PMEO患者中11.5%的人NSE升高，NNP患者中2.8%的人NSE升高。治疗后完全缓解的SCLC患者NSE下降100%，反应不佳的患者中25%的人NSE下降。后来，81.2%复发的患者该标志物升高，其中6.2%在症状出现之前升高。初始NSE浓度具有预后价值（p = 0.003），且独立于疾病分期（LD或ED）。NSE在SCLC中具有重要的诊断和预后价值，能准确反映肿瘤大小。治疗后的变化与疾病活动密切平行。
